AMD is the leading cause of irreversible vision loss in the elderly in the USA. There is currently no effective therapy for the late “dry” form of the disease (pictured here). Dr. Hinton performs basic studies of AMD pathogenesis as well as translational studies to find potential therapeutic interventions. He is Co-PI of a project utilizing stem cell-derived retinal pigment epithelial cells grown as a monolayer on a substrate that is currently in Phase 1/11a clinical trial.
David Hinton enjoys spending time with his family, friends and colleagues. He travels extensively and especially enjoys adventurous cuisines and outdoor activities. Recent adventures included climbing the Sydney Harbour Bridge and descending to the interior of a volcano in Iceland.
Mitchell Gross, MD, PhD
Caltech, Biology Graduate Option Administrator
Caltech, Staff Support Associate